• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Case study: De-risking clinical development and driving therapeutic innovation in heart failure

Case study: De-risking clinical development and driving therapeutic innovation in heart failure

by Truveta staff | Sep 26, 2024 | Technology

Despite advances in guideline-directed medical therapy, heart failure (HF) readmission rates have worsened over the past decade. Optimizing acute inpatient decongestion is critical in mitigating HF morbidity and mortality, but few new treatment strategies have emerged...

Share this


Recent posts

  • GLP-1 RA prescription trends: January 2018 – June 2025
  • Pediatric fluoride prescriptions fall across the US
  • Truveta Experts: Real-world trends in Rituxan biosimilar adoption

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.